Does anyone have any info on this article? https://www.pcrm.org/news/news-releases/citiz...grity-ohsu
Bullish Technical Signals: Despite the FTD pressure, Tickeron technical analysis indicates an 84-85% probability of a continued upward trend based on recent stochastic oscillator reversals.Legal Headwinds: New citizen complaints filed with the OHSU Integrity Office on May 7, 2026, regarding past research practices continue to provide "fundamental" ammunition for short sellers.
As of May 9, 2026, CytoDyn (CYDY) short interest increased to 36.63 million shares, yet the "Days to Cover" dropped to 9.34 days due to higher trading volume during the recent price recovery. While total shorted shares rose, the increased velocity in price recovery reduced the time needed for shorts to cover. For more detailed data, see Benzinga. https://www.benzinga.com/quote/CYDY/short-interest
The possibility of naked short selling affecting CytoDyn (CYDY) is a subject of significant debate between market regulators, retail investors, and financial analysts. While the SEC has regulations to prevent it, the OTC market's lower transparency often makes it a prime target for such activity.
As of May 2026, CytoDyn's public short interest is relatively stable, but specific indicators suggest ongoing pressure:Reported Short Interest: Approximately 36.63 million shares are currently sold short, representing about 2.68% of the public float.Fails-to-Deliver (FTD): Data from Fintel shows recurring "fails-to-deliver" for CYDY, reaching peaks of over 5 million shares in late 2025 and early 2026. High FTD counts are often cited by analysts as a primary indicator of naked short selling, where shares are sold but never actually delivered.Days to Cover: It would take roughly 9.34 to 12.5 days of average trading volume for all shorts to close their positions, indicating a potential for a short squeeze if positive news breaks.
Fails-to-Deliver (FTD) data for CytoDyn (CYDY) over the last six months shows several periods of elevated activity, with cumulative fails peaking at over 5 million shares. These spikes often lead to intense debate among retail investors regarding market manipulation and naked shorting
https://www.sec.gov/data-research/sec-markets...liver-data
Bullish Technical Signals: Despite the FTD pressure, Tickeron technical analysis indicates an 84-85% probability of a continued upward trend based on recent stochastic oscillator reversals.Legal Headwinds: New citizen complaints filed with the OHSU Integrity Office on May 7, 2026, regarding past research practices continue to provide "fundamental" ammunition for short sellers.
As of May 9, 2026, CytoDyn (CYDY) short interest increased to 36.63 million shares, yet the "Days to Cover" dropped to 9.34 days due to higher trading volume during the recent price recovery. While total shorted shares rose, the increased velocity in price recovery reduced the time needed for shorts to cover. For more detailed data, see Benzinga. https://www.benzinga.com/quote/CYDY/short-interest
The possibility of naked short selling affecting CytoDyn (CYDY) is a subject of significant debate between market regulators, retail investors, and financial analysts. While the SEC has regulations to prevent it, the OTC market's lower transparency often makes it a prime target for such activity.
As of May 2026, CytoDyn's public short interest is relatively stable, but specific indicators suggest ongoing pressure:Reported Short Interest: Approximately 36.63 million shares are currently sold short, representing about 2.68% of the public float.Fails-to-Deliver (FTD): Data from Fintel shows recurring "fails-to-deliver" for CYDY, reaching peaks of over 5 million shares in late 2025 and early 2026. High FTD counts are often cited by analysts as a primary indicator of naked short selling, where shares are sold but never actually delivered.Days to Cover: It would take roughly 9.34 to 12.5 days of average trading volume for all shorts to close their positions, indicating a potential for a short squeeze if positive news breaks.
Fails-to-Deliver (FTD) data for CytoDyn (CYDY) over the last six months shows several periods of elevated activity, with cumulative fails peaking at over 5 million shares. These spikes often lead to intense debate among retail investors regarding market manipulation and naked shorting
https://www.sec.gov/data-research/sec-markets...liver-data
1
